Putting the Guidelines Into Practice: Building a State-of-the-Art Lipid and Cardiometabolic Clinic (Session 3001)
Saturday, March 28
5:45 – 7:15 p.m. | La Nouvelle Ballroom B

As lipid and cardiometabolic care rapidly evolves, clinicians face increasing complexity in risk assessment, treatment intensification, and long‑term management. Led by Eugenia Gianos, MD, FACC, this session provides practical guidance on building and optimizing a high‑functioning lipid and cardiometabolic clinic aligned with current and emerging guidelines. Explore modern risk assessment tools, increasingly stringent LDL‑C targets, and the expanding role of biomarkers such as apoB, Lp(a), and coronary artery calcium scoring. Learn strategies to manage residual risk, statin intolerance, and the appropriate use of non‑statin and combination therapies, with special focus on high‑risk populations, including patients with chronic kidney disease, and sustainable, team‑based care models.

Supported by educational grants from Amgen and Esperion

Hypertriglyceridemia and Cardiovascular Health: Recognizing Risks and Tackling Management (Session 3003)
Sunday, March 29
6 – 7:30 p.m. | La Nouvelle Ballroom B

Hypertriglyceridemia — particularly in its severe forms — poses significant cardiovascular and pancreatitis risk yet remains challenging to manage in clinical practice. Led by Michael Miller, MD, FACC, this case‑based session explores the full clinical spectrum of hypertriglyceridemia, from common multifactorial disease to rare genetic disorders such as familial chylomicronemia syndrome (FCS). Gain practical strategies to recognize risk, evaluate genetic, metabolic, medication‑related, and dietary contributors, and select appropriate therapies. The discussion will also highlight multidisciplinary care models and emerging treatments, including apoC‑III inhibitors, to improve outcomes in complex patients.

Supported by an educational grant from Ionis Pharmaceuticals